Thomas S. Lytle, BBA, MBA, Chief Executive Officer & Board Member
Mr. Lytle has over 40 years of commercial experience in the pharmaceutical and biotechnology industry, and has held senior level positions with market leading companies including Pfizer and Amgen. He launched Strategic Choices, LLC, a well-networked healthcare consulting practice, focused on helping emerging companies achieve key objectives. In 2006, he was elected to the Board of Directors of Neogenix Oncology, a clinical stage oncology therapeutics and diagnostic company focusing on pancreatic and other cancers. He also served as Chief Operating and Administrative Officer for the firm until January 2011. He established Melanovus Oncology as President & CEO and lead the company to a successful exit.